Abstract 2899: Mitophagy imparts enzalutamide resistance in prostate cancer

Hirak S. Basu, Cynthia L. Schrieber,Jamie M. Sperger, Maryanne Naundorf, Ashley M. Weichman,Farideh Mehraein-Ghomi,Dawn R. Church,Joshua M. Lang,George Wilding

Cancer Research（2015）

引用 1|浏览18

暂无评分

摘要

Purpose: Anti-androgens are widely used in androgen deprivation therapy (ADT), a standard-of-care for patients with recurrent prostate cancer (PCa). Unfortunately, most patients ultimately develop resistance to ADT and progress to castrate-resistant prostate cancer (CRPC). Recently, two agents that block androgen receptor activation [abiraterone acetate (Zytiga, JJ 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2899. doi:10.1158/1538-7445.AM2015-2899

查看译文

关键词

mitophagy,prostate cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要